Nanotechnology-enabled modulation of reactive oxygen species in cancer and chronic inflammation: a systematic review of therapeutic advances and translational challenges
Source abstract
Abstract
BACKGROUND: Reactive oxygen species (ROS) are key regulators of cellular signalling and homeostasis, but if not managed, they can cause genomic instability, activation of carcinogenic pathways, and chronic inflammation. Approaches to ROS regulation using nanotechnology have demonstrated promise in preclinical models of inflammatory disorders and cancer but have yet to be transferred clinically due to concerns about specificity, safety, measurement, and standardization in redox regulation. MAIN BODY: The aim of this study was to assess nanotechnology strategies for achieving spatiotemporally controlled ROS modulation, highlighting technical challenges, safety issues, and translation barriers. We conducted a PRISMA 2020 systematic review (2013-2023) across PubMed, Scopus, and Web of Science. Eligible publications were screened using preset criteria; bias was assessed with SYRCLE. We synthesised nanomaterial classes, ROS-modulating mechanisms, therapeutic effects, and translational hurdles. We separately summarise findings for cancer and for chronic inflammation, then integrate convergences. Key findings include: ROS-induced genotoxic stress promotes malignant transformation and therapy resistance; persistent oxidative signalling enhances NF-κB/AP-1 activation and M1 polarisation, driving fibrosis and chronic inflammation. Harmonised procedures are necessary to address safety and standardisation issues, including chronic toxicity, immunogenicity, and inter-laboratory assay variation. Biomarker-stratified trials outperformed unstratified designs, and combination nanotherapies improved cancer cell kill over monotherapies. CONCLUSION: Nanotechnology-based ROS regulation is promising for cancer and chronic inflammatory illnesses but requires high-precision subcellular targeting, dual-threshold release, complete safety profiling, standardised ROS assays, and unified biomarker platforms for translation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.10.1038/nature01322 ↗
2. Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34(35):4270–6. https://doi.org/10.1200/JCO.2016.67.4283.10.1200/JCO.2016.67.4283 ↗
3. Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. https://doi.org/10.1186/s12199-018-0740-1.10.1186/s12199-018-0740-1 ↗
4. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16. https://doi.org/10.1016/j.freeradbiomed.2010.09.006.10.1016/j.freeradbiomed.2010.09.006 ↗
5. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199–245. https://doi.org/10.1016/bs.apcsb.2019.09.004.10.1016/bs.apcsb.2019.09.004 ↗
6. Fernandes Q, Inchakalody VP, Bedhiafi T, Mestiri S, Taib N, Uddin S, et al. Chronic inflammation and cancer; the two sides of a coin. Life Sci. 2024;338:122390. https://doi.org/10.1016/j.lfs.2023.122390.10.1016/j.lfs.2023.122390 ↗
7. Korbecki J, Simińska D, Gąssowska-Dobrowolska M, Listos J, Gutowska I, Chlubek D, et al. Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: a review of the molecular mechanisms. Int J Mol Sci. 2021;22(19):10701. https://doi.org/10.3390/ijms221910701.10.3390/ijms221910701 ↗
8. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(3):285–311. https://doi.org/10.4093/dmj.2020.0250.10.4093/dmj.2020.0250 ↗
9. Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4(3):176–85. https://doi.org/10.1007/s13238-013-2084-3.10.1007/s13238-013-2084-3 ↗
10. Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med. 2018;42(2):713–25. https://doi.org/10.3892/ijmm.2018.3689.10.3892/ijmm.2018.3689 ↗
11. Sohrab SS, Raj R, Nagar A, Hawthorne S, Paiva-Santos AC, Kamal MA, et al. Chronic inflammation’s transformation to cancer: a nanotherapeutic paradigm. Molecules. 2023;28(11):4413. https://doi.org/10.3390/molecules28114413.10.3390/molecules28114413 ↗
12. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–25. https://doi.org/10.1038/s41568-019-0144-6.10.1038/s41568-019-0144-6 ↗
13. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71. https://doi.org/10.1038/nrc3611.10.1038/nrc3611 ↗
14. Maiorino L, Daßler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17(1):425–57. https://doi.org/10.1146/annurev-pathmechdis-032221-115501.10.1146/annurev-pathmechdis-032221-115501 ↗
15. Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–61. https://doi.org/10.1038/s41577-020-0406-2.10.1038/s41577-020-0406-2 ↗
16. Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine. Molecules. 2019;25(1):112. https://doi.org/10.3390/molecules25010112.10.3390/molecules25010112 ↗
17. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37. https://doi.org/10.1038/nrc.2016.108.10.1038/nrc.2016.108 ↗
18. Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–14. https://doi.org/10.1016/j.trecan.2022.07.002.10.1016/j.trecan.2022.07.002 ↗
19. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571–80. https://doi.org/10.1016/j.it.2014.09.006.10.1016/j.it.2014.09.006 ↗
20. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543–88. https://doi.org/10.7150/thno.15625.10.7150/thno.15625 ↗
21. Zhang Q, Wu S. Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. Front Immunol. 2023;13:1063711. https://doi.org/10.3389/fimmu.2022.1063711.10.3389/fimmu.2022.1063711 ↗
22. Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019;118:109249. https://doi.org/10.1016/j.biopha.2019.109249.10.1016/j.biopha.2019.109249 ↗
23. Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol. 2018;1095:41–65. https://doi.org/10.1007/978-3-319-95693-0_3.10.1007/978-3-319-95693-0_3 ↗
24. Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer J. 2014;20(3):181–9. https://doi.org/10.1097/PPO.0000000000000048.10.1097/PPO.0000000000000048 ↗
25. Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023;79(2):538–51. https://doi.org/10.1016/j.jhep.2023.02.033.10.1016/j.jhep.2023.02.033 ↗
26. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002 Feb;16(2):217–26, 229; discussion 230–2.
27. Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133. https://doi.org/10.1186/s12943-020-01250-1.10.1186/s12943-020-01250-1 ↗
28. Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127–37. https://doi.org/10.1016/j.pharmthera.2017.02.025.10.1016/j.pharmthera.2017.02.025 ↗
29. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–39. https://doi.org/10.1016/j.pharmthera.2013.09.004.10.1016/j.pharmthera.2013.09.004 ↗
30. Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96. https://doi.org/10.1016/bs.acr.2015.04.014.10.1016/bs.acr.2015.04.014 ↗
31. Chang SC, Yang WV. Hyperglycemia, tumorigenesis, and chronic inflammation. Crit Rev Oncol Hematol. 2016;108:146–53. https://doi.org/10.1016/j.critrevonc.2016.11.003.10.1016/j.critrevonc.2016.11.003 ↗
32. Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzeroni F. Cancer secretome and inflammation: the bright and the dark sides of NF-κB. Semin Cell Dev Biol. 2018;78:51–61. https://doi.org/10.1016/j.semcdb.2017.08.004.10.1016/j.semcdb.2017.08.004 ↗
33. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–96. https://doi.org/10.1038/nrclinonc.2015.105.10.1038/nrclinonc.2015.105 ↗
34. Malhab LJB, Saber-Ayad MM, Al-Hakm R, Nair VA, Paliogiannis P, Pintus G, et al. Chronic inflammation and cancer: the role of endothelial dysfunction and vascular inflammation. Curr Pharm Des. 2021;27(18):2156–69. https://doi.org/10.2174/1381612827666210303143442.10.2174/1381612827666210303143442 ↗
35. Michels N, van Aart C, Morisse J, Mullee A, Huybrechts I. Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol. 2021;157:103177. https://doi.org/10.1016/j.critrevonc.2020.103177.10.1016/j.critrevonc.2020.103177 ↗
36. Kiely M, Lord B, Ambs S. Immune response and inflammation in cancer health disparities. Trends Cancer. 2022;8(4):316–27. https://doi.org/10.1016/j.trecan.2021.11.010.10.1016/j.trecan.2021.11.010 ↗
37. Raposo TP, Beirão BC, Pang LY, Queiroga FL, Argyle DJ. Inflammation and cancer: till death tears them apart. Vet J. 2015;205(2):161–74. https://doi.org/10.1016/j.tvjl.2015.04.015.10.1016/j.tvjl.2015.04.015 ↗
38. Gudkov AV, Komarova EA. p53 and the carcinogenicity of chronic inflammation. Cold Spring Harb Perspect Med. 2016;6(11):a026161. https://doi.org/10.1101/cshperspect.a026161.10.1101/cshperspect.a026161 ↗
39. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011 Apr 30;25(5):400–10, 413.
40. Nguyen AH, Berim IG, Agrawal DK. Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells. Expert Rev Clin Immunol. 2015;11(7):849–57. https://doi.org/10.1586/1744666X.2015.1043893.10.1586/1744666X.2015.1043893 ↗
41. Gupta SC, Kunnumakkara AB, Aggarwal S, Aggarwal BB. Inflammation, a double-edge sword for cancer and other age-related diseases. Front Immunol. 2018;9:2160. https://doi.org/10.3389/fimmu.2018.02160.10.3389/fimmu.2018.02160 ↗
42. Müzes G, Sipos F. Inflammasome, inflammation and cancer: an interrelated pathobiological triad. Curr Drug Targets. 2015;16(3):249–57. https://doi.org/10.2174/1389450115666141229154157.10.2174/1389450115666141229154157 ↗
43. Fichtner-Feigl S, Kesselring R, Strober W. Chronic inflammation and the development of malignancy in the GI tract. Trends Immunol. 2015;36(8):451–9. https://doi.org/10.1016/j.it.2015.06.007.10.1016/j.it.2015.06.007 ↗
44. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–32. https://doi.org/10.1038/s41590-018-0044-z.10.1038/s41590-018-0044-z ↗
45. Pesic M, Greten FR. Inflammation and cancer: tissue regeneration gone awry. Curr Opin Cell Biol. 2016;43:55–61. https://doi.org/10.1016/j.ceb.2016.07.010.10.1016/j.ceb.2016.07.010 ↗
46. Maiuri AR, O’Hagan HM. Interplay between inflammation and epigenetic changes in cancer. Prog Mol Biol Transl Sci. 2016;144:69–117. https://doi.org/10.1016/bs.pmbts.2016.09.002.10.1016/bs.pmbts.2016.09.002 ↗
47. Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11(7):805–23. https://doi.org/10.1002/1878-0261.12095.10.1002/1878-0261.12095 ↗
48. Khan S, Jain M, Mathur V, Feroz SM. Chronic inflammation and cancer: paradigm on tumor progression, metastasis and therapeutic intervention. Gulf J Oncolog. 2016;1(20):86–93.
49. Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett. 2014;345(2):174–81. https://doi.org/10.1016/j.canlet.2013.07.030.10.1016/j.canlet.2013.07.030 ↗
50. Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J. 2015;468(1):1–15. https://doi.org/10.1042/BJ20141337.10.1042/BJ20141337 ↗
51. Bhatelia K, Singh K, Singh R. TLRs: linking inflammation and breast cancer. Cell Signal. 2014;26(11):2350–7. https://doi.org/10.1016/j.cellsig.2014.07.035.10.1016/j.cellsig.2014.07.035 ↗
52. Amere Subbarao S. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology. 2021;29(2):343–66. https://doi.org/10.1007/s10787-021-00796-w.10.1007/s10787-021-00796-w ↗
53. Afify SM, Hassan G, Seno A, Seno M. Cancer-inducing niche: the force of chronic inflammation. Br J Cancer. 2022;127(2):193–201. https://doi.org/10.1038/s41416-022-01775-w.10.1038/s41416-022-01775-w ↗
54. Woller N, Kühnel F. Virus infection, inflammation and prevention of cancer. Recent Results Cancer Res. 2014;193:33–58. https://doi.org/10.1007/978-3-642-38965-8_3.10.1007/978-3-642-38965-8_3 ↗
55. Tian R, Zuo X, Jaoude J, Mao F, Colby J, Shureiqi I. ALOX15 as a suppressor of inflammation and cancer: lost in the link. Prostaglandins Other Lipid Mediat. 2017;132:77–83. https://doi.org/10.1016/j.prostaglandins.2017.01.002.10.1016/j.prostaglandins.2017.01.002 ↗
56. Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer: an overview. Cancer Lett. 2014;345(2):153–6. https://doi.org/10.1016/j.canlet.2013.08.025.10.1016/j.canlet.2013.08.025 ↗
57. Song XD, Wang YN, Zhang AL, Liu B. Advances in research on the interaction between inflammation and cancer. J Int Med Res. 2020;48(4):300060519895347. https://doi.org/10.1177/0300060519895347.10.1177/0300060519895347 ↗
58. Manjili SH, Isbell M, Ghochaghi N, Perkinson T, Manjili MH. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Semin Cancer Biol. 2022;78:17–22. https://doi.org/10.1016/j.semcancer.2021.03.023.10.1016/j.semcancer.2021.03.023 ↗
59. Zhang X, Meng X, Chen Y, Leng SX, Zhang H. The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J. 2017;23(4):201–5. https://doi.org/10.1097/PPO.0000000000000270.10.1097/PPO.0000000000000270 ↗
60. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82–91. https://doi.org/10.1016/j.coph.2015.05.017.10.1016/j.coph.2015.05.017 ↗
61. Talero E, García-Mauriño S, Ávila-Román J, Rodríguez-Luna A, Alcaide A, Motilva V. Bioactive compounds isolated from microalgae in chronic inflammation and cancer. Mar Drugs. 2015;13(10):6152–209. https://doi.org/10.3390/md13106152.10.3390/md13106152 ↗
62. Khatami M. Unresolved inflammation: “immune tsunami” or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Expert Opin Biol Ther. 2011;11(11):1419–32. https://doi.org/10.1517/14712598.2011.592826.10.1517/14712598.2011.592826 ↗
63. Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014;49(2):116–39. https://doi.org/10.3109/10409238.2013.875514.10.3109/10409238.2013.875514 ↗
64. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? Biochem Pharmacol. 2006;72(11):1605–21. https://doi.org/10.1016/j.bcp.2006.06.029.10.1016/j.bcp.2006.06.029 ↗
65. Zhang YG, Niu JT, Wu HW, Si XL, Zhang SJ, Li DH, et al. Actin-binding proteins as potential biomarkers for chronic inflammation-induced cancer diagnosis and therapy. Anal Cell Pathol. 2021;2021:6692811. https://doi.org/10.1155/2021/6692811.10.1155/2021/6692811 ↗
66. Cutolo M, Paolino S, Pizzorni C. Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol. 2014;32(6):839–47.
67. Ungefroren H, Gieseler F, Fliedner S, Lehnert H. Obesity and cancer. Horm Mol Biol Clin Investig. 2015;21(1):5–15. https://doi.org/10.1515/hmbci-2014-0046.10.1515/hmbci-2014-0046 ↗
68. Meirow Y, Baniyash M. Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases. Cancer Immunol Immunother. 2017;66(8):1089–101. https://doi.org/10.1007/s00262-017-2035-6.10.1007/s00262-017-2035-6 ↗
69. Kufe DW. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020;41(9):1173–83. https://doi.org/10.1093/carcin/bgaa082.10.1093/carcin/bgaa082 ↗
70. Payne JK. State of the science: stress, inflammation, and cancer. Oncol Nurs Forum. 2014;41(5):533–40. https://doi.org/10.1188/14.ONF.533-540.10.1188/14.ONF.533-540 ↗
71. Quinn KM, Kartikasari AER, Cooke RE, Koldej RM, Ritchie DS, Plebanski M. Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy. J Leukoc Biol. 2020;108(3):953–65. https://doi.org/10.1002/JLB.5MR0520-466R.10.1002/JLB.5MR0520-466R ↗
72. Kumar S, Mehta K. Tissue transglutaminase, inflammation, and cancer: How intimate is the relationship? Amino Acids. 2013;44(1):81–8. https://doi.org/10.1007/s00726-011-1139-0.10.1007/s00726-011-1139-0 ↗
73. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008;18(1):3–10. https://doi.org/10.1016/j.gde.2008.01.003.10.1016/j.gde.2008.01.003 ↗
74. Aggarwal BB, Gehlot P. Inflammation and cancer: How friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9(4):351–69. https://doi.org/10.1016/j.coph.2009.06.020.10.1016/j.coph.2009.06.020 ↗
75. Ptak-Belowska A, Targosz A, Brzozowski T. MicroRNAs and chronic inflammation contribution to gastrointestinal integrity. Curr Med Chem. 2012;19(1):133–6. https://doi.org/10.2174/092986712803413999.10.2174/092986712803413999 ↗
76. Amin MN, Hussain MS, Sarwar MS, Rahman Moghal MM, Das A, Hossain MZ, et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab Syndr. 2019;13(2):1213–24. https://doi.org/10.1016/j.dsx.2019.01.041.10.1016/j.dsx.2019.01.041 ↗
77. Dmitrieva OS, Shilovskiy IP, Khaitov MR, Grivennikov SI. Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry. 2016;81(2):80–90. https://doi.org/10.1134/S0006297916020024.10.1134/S0006297916020024 ↗
78. Hirakawa S, Detmar M, Karaman S. Lymphatics in nanophysiology. Adv Drug Deliv Rev. 2014;74:12–8. https://doi.org/10.1016/j.addr.2014.01.011.10.1016/j.addr.2014.01.011 ↗
79. Boopathi E, Thangavel C. Dark side of cancer therapy: cancer treatment-induced cardiopulmonary inflammation, fibrosis, and immune modulation. Int J Mol Sci. 2021;22(18):10126. https://doi.org/10.3390/ijms221810126.10.3390/ijms221810126 ↗
80. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30(1):677–706. https://doi.org/10.1146/annurev-immunol-020711-075008.10.1146/annurev-immunol-020711-075008 ↗
81. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31(1):37–49. https://doi.org/10.1093/carcin/bgp272.10.1093/carcin/bgp272 ↗
82. Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96(4):449–57. https://doi.org/10.1038/clpt.2014.143.10.1038/clpt.2014.143 ↗
83. Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis. 2019;77(5):ftz048. https://doi.org/10.1093/femspd/ftz048.10.1093/femspd/ftz048 ↗
84. Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018;67(10):801–12. https://doi.org/10.1007/s00011-018-1173-4.10.1007/s00011-018-1173-4 ↗
85. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009;8(13):2005–13. https://doi.org/10.4161/cc.8.13.8985.10.4161/cc.8.13.8985 ↗
86. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012;33(4):723–31. https://doi.org/10.1093/carcin/bgs006.10.1093/carcin/bgs006 ↗
87. Jha NK, Arfin S, Jha SK, Kar R, Dey A, Gundamaraju R, et al. Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling. Semin Cancer Biol. 2022;86(Pt 2):1086–104. https://doi.org/10.1016/j.semcancer.2022.02.022.10.1016/j.semcancer.2022.02.022 ↗
88. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381–6. https://doi.org/10.1002/ijc.23192.10.1002/ijc.23192 ↗
89. Liu W, Rodgers GP. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Cancer Metastasis Rev. 2016;35(2):201–12. https://doi.org/10.1007/s10555-016-9624-2.10.1007/s10555-016-9624-2 ↗
90. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831–52. https://doi.org/10.2174/138161212802083707.10.2174/138161212802083707 ↗
91. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–8. https://doi.org/10.1038/clpt.2009.254.10.1038/clpt.2009.254 ↗
92. Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. Novartis Found Symp. 2004;256:6-21; discussion 22-8, 49-52, 266-9.10.1002/0470856734.ch2 ↗
93. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69–83. https://doi.org/10.3322/canjclin.56.2.69.10.3322/canjclin.56.2.69 ↗
94. Dobrovolskaia MA, Kozlov SV. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets. 2005;5(5):325–44. https://doi.org/10.2174/1568009054629645.10.2174/1568009054629645 ↗
95. Weber D, Wheat JM, Curri GM. Inflammation and cancer: tumor initiation, progression and metastasis, and Chinese botanical medicines. J Chin Integr Med. 2010;8(11):1006–13. https://doi.org/10.3736/jcim20101101.10.3736/jcim20101101 ↗
96. Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer. Int J Mol Sci. 2021;22(15):8340–8340. https://doi.org/10.3390/ijms22158340.10.3390/ijms22158340 ↗
97. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85(1):141–7. https://doi.org/10.1139/y06-093.10.1139/y06-093 ↗
98. Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2011;305(2):250–62. https://doi.org/10.1016/j.canlet.2010.10.012.10.1016/j.canlet.2010.10.012 ↗
99. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013–37. https://doi.org/10.1016/j.freeradbiomed.2012.02.035.10.1016/j.freeradbiomed.2012.02.035 ↗
100. Batista ML Jr, Peres SB, McDonald ME, Alcantara PS, Olivan M, Otoch JP, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine. 2012;57(1):9–16. https://doi.org/10.1016/j.cyto.2011.10.008.10.1016/j.cyto.2011.10.008 ↗